Cutaneous toxicity of the targeted therapy of malignant neoplasms

Nowadays an overwhelming majority of new antitumoral drugs belong to targeted agents. The principle of action of such targeted agents consists in blocking the key signalling target both in a tumour and in normal cells. This results in a wide range of adverse events (AE). One of the most frequent AE of targeted therapy are skin and its appentages reactions observed in 60-100% of patients being treated with EGFR inhibitors and in 10-60% of those treated with mTOR inhibitors. Such AE constitute a serious clinical problem as they considerably worsen the patients' quality of life and necessitate to reduce the dose of the drug or even discontinue the therapy. The review contains detailed descriptions of cutaneous AE which occur in the course of tyrosine kinase inhibitors, as well as a treatment options for their therapy. © 2022 Izdatel'stvo Meditsina. All rights reserved.